United States Biotechnology & Medical Research

Atea Pharmaceuticals Inc (AVIR)

Track

Track

Atea Pharmaceuticals Inc. has seen no insider trading activity within the last ninety days. The most recent recorded transaction occurred on May 18, 2025, involving a purchase of shares. Prior historical data indicates various sell orders executed by company leadership and affiliates throughout 2024.
Ticker: AVIR Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Atea Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.8
Murphy Polly A. Non-Executive Director
Transaction date
Purchase
Price
67.02
Quantity 76,003 +21.8%
Value US$1,332,460
2.3
BERGER FRANKLIN M Non-Executive Director
Transaction date
Sale
Price
345.80
Quantity 28,351 +37.3%
Value US$3,417,050
2.3
Franklin Berger Lead Independent Director Non-Executive Director
Transaction date
Proposed sale
Price
310.65
Quantity 57,426
Value US$680,021
JPM Partners LLC Affiliate
Transaction date
Proposed sale
Price
4.00
Quantity 1,841
Value US$7,367
3.7
Sommadossi Jean-Pierre President, CEO, and Chairman Executive Director
Transaction date
Sale
Price
4.00
Quantity 1,841 -0.0%
Value US$7,367
3.7
Sommadossi Jean-Pierre President, CEO, and Chairman Executive Director
Transaction date
Sale
Price
4.03
Quantity 22,187 -0.4%
Value US$89,469
JPM Partners LLC Affiliate
Transaction date
Proposed sale
Price
4.03
Quantity 22,187
Value US$89,469
3.7
Sommadossi Jean-Pierre President, CEO, and Chairman Executive Director
Transaction date
Sale
Price
4.05
Quantity 33,941 -0.6%
Value US$137,318
JPM Partners LLC Affiliate
Transaction date
Proposed sale
Price
4.05
Quantity 33,941
Value US$137,318
0.8
Polsky Bruce Non-Executive Director
Transaction date
Sale
Price
3.49
Quantity 17,544 -21.1%
Value US$61,144
0.8
Polsky Bruce Director Non-Executive Director
Transaction date
Proposed sale
Price
3.92
Quantity 17,544
Value US$68,772
3.7
Sommadossi Jean-Pierre President, CEO, and Chairman Executive Director
Transaction date
Sale
Price
4.00
Quantity 1,006 -0.0%
Value US$4,024
JPM Partners LLC Affiliate
Transaction date
Proposed sale
Price
4.00
Quantity 1,006
Value US$4,024
Hammond Janet MJ Chief Development Officer Officer
Transaction date
Planned sale
Price
3.84
Quantity 14,029 -28.4%
Value US$53,913
Horga Maria Arantxa Chief Medical Officer Officer
Transaction date
Planned sale
Price
3.84
Quantity 15,870 -38.2%
Value US$60,963
Foster Wayne EVP, Chief Accounting Officer Officer
Transaction date
Planned sale
Price
3.84
Quantity 12,477 -37.4%
Value US$47,904
3.7
Sommadossi Jean-Pierre President, CEO, and Chairman Executive Director
Transaction date
Planned sale
Price
3.85
Quantity 56,910 -32.8%
Value US$218,819
Corcoran Andrea See Remarks Officer
Transaction date
Planned sale
Price
3.84
Quantity 15,843 -2.3%
Value US$60,915
Vavricka John Chief Commercial Officer Officer
Transaction date
Planned sale
Price
3.84
Quantity 11,819 -35.5%
Value US$45,420
Wayne Foster EVP, Chief Accounting Officer Officer
Transaction date
Proposed sale
Price
4.07
Quantity 14,311
Value US$58,246
3.7
Jean-Pierre Sommadossi President, CEO, and Chairman
Transaction date
Proposed sale
Price
4.07
Quantity 65,476
Value US$266,487
Janet MJ Hammond Chief Development Officer Officer
Transaction date
Proposed sale
Price
4.07
Quantity 16,110
Value US$65,568
John Vavricka Chief Commercial Officer Officer
Transaction date
Proposed sale
Price
4.07
Quantity 13,552
Value US$55,157
Maria Arantxa Horga Chief Medical Officer Officer
Transaction date
Proposed sale
Price
4.07
Quantity 18,227
Value US$74,184
Andrea Corcoran CFO, EVP, Legal and Secretary
Transaction date
Proposed sale
Price
4.07
Quantity 18,198
Value US$74,066
2.3
BERGER FRANKLIN M Non-Executive Director
Transaction date
Sale
Price
5.16
Quantity 16,166 -2.0%
Value US$83,352
2.3
BERGER FRANKLIN M Non-Executive Director
Transaction date
Sale
Price
5.15
Quantity 25,500 -3.1%
Value US$131,333
1.8
Murphy Polly A. Non-Executive Director
Transaction date
Purchase
Price
8.57
Quantity 12,000 +106.2%
Value US$102,796
2.3
BERGER FRANKLIN M Non-Executive Director
Transaction date
Purchase
Price
24.00
Quantity 41,666 +5.4%
Value US$999,984
3.3
Hack Andrew A. F. Non-Executive Director
Transaction date
Purchase
Price
24.00
Quantity 250,000 +4.7%
Value US$6,000,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-20 2025-05-18 B Purchase
1.8
Murphy Polly A.
Non-Executive Director
76,003 +21.8%
67.02
US$1,332,460 		76,003 +21.8% 67.02 US$1,332,460
2024-12-12 2024-12-10 S Sale
2.3
BERGER FRANKLIN M
Non-Executive Director
28,351 +37.3%
345.80
US$3,417,050 		28,351 +37.3% 345.80 US$3,417,050
2024-12-10 2024-12-10 PrS Proposed sale
2.3
Franklin Berger

Lead Independent Director

Non-Executive Director
57,426
310.65
US$680,021 		57,426 310.65 US$680,021
2024-09-19 2024-09-19 PrS Proposed sale
JPM Partners LLC

Affiliate
1,841
4.00
US$7,367 		1,841 4.00 US$7,367
2024-09-19 2024-09-19 S Sale
3.7
Sommadossi Jean-Pierre

President, CEO, and Chairman

Executive Director
1,841 -0.0%
4.00
US$7,367 		1,841 -0.0% 4.00 US$7,367
2024-09-19 2024-09-18 S Sale
3.7
Sommadossi Jean-Pierre

President, CEO, and Chairman

Executive Director
22,187 -0.4%
4.03
US$89,469 		22,187 -0.4% 4.03 US$89,469
2024-09-18 2024-09-18 PrS Proposed sale
JPM Partners LLC

Affiliate
22,187
4.03
US$89,469 		22,187 4.03 US$89,469
2024-09-19 2024-09-17 S Sale
3.7
Sommadossi Jean-Pierre

President, CEO, and Chairman

Executive Director
33,941 -0.6%
4.05
US$137,318 		33,941 -0.6% 4.05 US$137,318
2024-09-17 2024-09-17 PrS Proposed sale
JPM Partners LLC

Affiliate
33,941
4.05
US$137,318 		33,941 4.05 US$137,318
2024-06-21 2024-06-20 S Sale
0.8
Polsky Bruce
Non-Executive Director
17,544 -21.1%
3.49
US$61,144 		17,544 -21.1% 3.49 US$61,144
2024-06-20 2024-06-20 PrS Proposed sale
0.8
Polsky Bruce

Director

Non-Executive Director
17,544
3.92
US$68,772 		17,544 3.92 US$68,772
2024-06-07 2024-06-05 S Sale
3.7
Sommadossi Jean-Pierre

President, CEO, and Chairman

Executive Director
1,006 -0.0%
4.00
US$4,024 		1,006 -0.0% 4.00 US$4,024
2024-06-05 2024-06-05 PrS Proposed sale
JPM Partners LLC

Affiliate
1,006
4.00
US$4,024 		1,006 4.00 US$4,024
2024-02-02 2024-02-01 PlS Planned sale
Hammond Janet MJ

Chief Development Officer

Officer
14,029 -28.4%
3.84
US$53,913 		14,029 -28.4% 3.84 US$53,913
2024-02-02 2024-02-01 PlS Planned sale
Horga Maria Arantxa

Chief Medical Officer

Officer
15,870 -38.2%
3.84
US$60,963 		15,870 -38.2% 3.84 US$60,963
2024-02-02 2024-02-01 PlS Planned sale
Foster Wayne

EVP, Chief Accounting Officer

Officer
12,477 -37.4%
3.84
US$47,904 		12,477 -37.4% 3.84 US$47,904
2024-02-02 2024-02-01 PlS Planned sale
3.7
Sommadossi Jean-Pierre

President, CEO, and Chairman

Executive Director
56,910 -32.8%
3.85
US$218,819 		56,910 -32.8% 3.85 US$218,819
2024-02-02 2024-02-01 PlS Planned sale
Corcoran Andrea

See Remarks

Officer
15,843 -2.3%
3.84
US$60,915 		15,843 -2.3% 3.84 US$60,915
2024-02-02 2024-02-01 PlS Planned sale
Vavricka John

Chief Commercial Officer

Officer
11,819 -35.5%
3.84
US$45,420 		11,819 -35.5% 3.84 US$45,420
2024-02-01 2024-02-01 PrS Proposed sale
Wayne Foster

EVP, Chief Accounting Officer

Officer
14,311
4.07
US$58,246 		14,311 4.07 US$58,246
2024-02-01 2024-02-01 PrS Proposed sale
3.7
Jean-Pierre Sommadossi

President, CEO, and Chairman
65,476
4.07
US$266,487 		65,476 4.07 US$266,487
2024-02-01 2024-02-01 PrS Proposed sale
Janet MJ Hammond

Chief Development Officer

Officer
16,110
4.07
US$65,568 		16,110 4.07 US$65,568
2024-02-01 2024-02-01 PrS Proposed sale
John Vavricka

Chief Commercial Officer

Officer
13,552
4.07
US$55,157 		13,552 4.07 US$55,157
2024-02-01 2024-02-01 PrS Proposed sale
Maria Arantxa Horga

Chief Medical Officer

Officer
18,227
4.07
US$74,184 		18,227 4.07 US$74,184
2024-02-01 2024-02-01 PrS Proposed sale
Andrea Corcoran

CFO, EVP, Legal and Secretary
18,198
4.07
US$74,066 		18,198 4.07 US$74,066
2022-11-15 2022-11-14 S Sale
2.3
BERGER FRANKLIN M
Non-Executive Director
16,166 -2.0%
5.16
US$83,352 		16,166 -2.0% 5.16 US$83,352
2022-11-15 2022-11-11 S Sale
2.3
BERGER FRANKLIN M
Non-Executive Director
25,500 -3.1%
5.15
US$131,333 		25,500 -3.1% 5.15 US$131,333
2021-12-21 2021-12-20 B Purchase
1.8
Murphy Polly A.
Non-Executive Director
12,000 +106.2%
8.57
US$102,796 		12,000 +106.2% 8.57 US$102,796
2020-11-04 2020-11-03 B Purchase
2.8
Rock Springs Capital Management LP
Large shareholder
7,292 +2.6%
24.00
US$175,008 		7,292 +2.6% 24.00 US$175,008
2020-11-04 2020-11-03 B Purchase
2.8
Rock Springs Capital Management LP
Large shareholder
242,708 +17.2%
24.00
US$5,824,992 		242,708 +17.2% 24.00 US$5,824,992
2020-11-03 2020-11-03 B Purchase
2.3
BERGER FRANKLIN M
Non-Executive Director
41,666 +5.4%
24.00
US$999,984 		41,666 +5.4% 24.00 US$999,984
2020-11-03 2020-11-03 B Purchase
3.3
Hack Andrew A. F.
Non-Executive Director
250,000 +4.7%
24.00
US$6,000,000 		250,000 +4.7% 24.00 US$6,000,000
Explore more

More insider trading research around Atea Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America